Clinical trials: sponsored by Canadian Cancer Trials Group
Breast Cancer
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen.
- Trial name
- ExCel (NCT00083174)
- Testing
- exemestane
- Where
- 76 sites in United States, Canada and 2 more
- Volunteers
- 4,560 people, healthy volunteers welcome
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
- Trial name
- NCT01622543
- Testing
- Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab
- Where
- 10 sites in Canada
- Volunteers
- 109 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
Observation or Radical Treatment in Patients With Prostate Cancer
RATIONALE: Sometimes prostate tumours may not need treatment until they progress. In this case, observation may be sufficient. Radical treatments, such as radical prostatectomy or radiation therapy, may be effective in treating…
- Trial name
- NCT00499174
- Testing
- conventional surgery, brachytherapy, external beam radiation therapy
- Where
- 13 sites in Canada
- Volunteers
- 180 people
- Sponsor
- NCIC Clinical Trials Group
Lymphoma
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00078949
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 849 people
- Sponsor
- NCIC Clinical Trials Group
Head and Neck Cancer
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00820248
- Testing
- panitumumab, cisplatin, 3-dimensional conformal radiation therapy
- Where
- 19 sites in Canada
- Volunteers
- 320 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Chronic Lymphocytic Leukemia
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
- Trial name
- NCT02340780
- Testing
- Buparlisib
- Where
- 6 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Cancer
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your prostate cancer. The investigators will also watch you carefully for any side effects that PX-866 might cause.
- Trial name
- NCT01331083
- Testing
- PX-866
- Where
- 10 sites in Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Urothelial Cancer
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
The purpose of this study is to compare the effects on urothelial cancer of nab-paclitaxel compared to paclitaxel to treat this disease.
- Trial name
- NCT02033993
- Testing
- Nab-Paclitaxel, Paclitaxel
- Where
- 37 sites in Australia, Canada
- Volunteers
- 199 people
- Sponsor
- Canadian Cancer Trials Group
Melanoma
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine.
- Trial name
- NCT01152788
- Testing
- rIL-21, Dacarbazine
- Where
- 19 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
RATIONALE: PF-00299804 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether PF-00299804 is more effective than a placebo in treating patients with advanced…
- Trial name
- NCT01000025
- Testing
- PF-00299804
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 720 people
- Sponsor
- NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00482677
- Testing
- temozolomide, DNA methylation analysis, quality-of-life assessment
- Where
- 22 sites in Canada, Germany and 2 more
- Volunteers
- 562 people
- Sponsor
- Canadian Cancer Trials Group
Glioblastoma
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
- Trial name
- NCT01259869
- Testing
- PX-866
- Where
- 7 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the tumor site and surrounding area may kill more tumor cells.
- Trial name
- NCT00005957
- Testing
- Standard Breast Irradiation, Breast Radiation plus Regional Radiation
- Where
- 26 sites in Canada
- Volunteers
- 1,832 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Cancer, Pain
Single vs Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether single-fraction (single-dose) re-irradiation therapy is as effective as multiple-fraction (many small doses of radiation…
- Trial name
- NCT00080912
- Testing
- radiation therapy
- Where
- 12 sites in Canada
- Volunteers
- 850 people
- Sponsor
- NCIC Clinical Trials Group
Brain and Central Nervous System Tumors
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00387400
- Testing
- everolimus, temozolomide, microarray analysis
- Where
- 9 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
Malignant Pleural Mesothelioma
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
- Trial name
- NCT01486368
- Testing
- PF-03446962
- Where
- 7 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00305812
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- 14 sites in Canada
- Volunteers
- 51 people
- Sponsor
- NCIC Clinical Trials Group
Bladder Cancer
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00352079
- Testing
- BCG vaccine, gefitinib, quality-of-life assessment
- Where
- 6 sites in Canada
- Volunteers
- 41 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to see how well they work in treating…
- Trial name
- NCT00255788
- Testing
- everolimus
- Where
- 5 sites in Canada
- Volunteers
- 49 people
- Sponsor
- NCIC Clinical Trials Group